secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001517022-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2
--------------------------------------------------------------------------------

- Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.
- Total Q4 prescribers ~785 (+8% QoQ); at least 25% of new patients from non-USRC centers (up from <10% Q3).
- First patient dosed in praliciguat Phase 2 trial for FSGS; AKB-097 basket study starts H2 2026.
- VOICE Phase IV fully enrolled (2,100+ patients); topline early 2027; VOCAL trial data expected Q4 2026.
- Revenue growth expected to resume Q1 2026; broad prescribing access to ~275,000 dialysis patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/0001517022-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/akba-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer